Skip to content

Dr. Molly Li

273
Dr. Molly Li
李兆澄
Share
qualifications
MBBS (HK) MRCP (UK) FHKCP FHKAM (medical oncology)
rank
Assistant Professor (Clinical) – Department of Clinical Oncology
orcid
0000-0002-6460-5514
email
molly@clo.cuhk.edu.hk

Specific Research / Sites of Interest

Lung Cancer

  • Clinical Trials

  • Lung Cancer in non-smokers

  • EGFR

  • Lung Cancer Screening

  • Biomarker development

  • Cellular Therapy

Short Biography

Dr Molly Li received his medical degree (MBBS) from the University of Hong Kong in 2014 with distinction in medicine. He obtained specialist qualification in Medical Oncology in 2021 and joined the Chinese University of Hong Kong as Assistant Professor in 2022. His research focus is on lung cancer.

Dr Li’s research areas range from preclinical research to clinical trials. He is currently the principal investigator or co-investigator of more than 20 lung cancer clinical trials. He is also the principal investigator of a multi-centre investigator-initiated phase 2 trial and a lung cancer screening study in Hong Kong. In preclinical research, he runs a laboratory focusing on stem cell therapy research in lung cancer and xenograft model establishing for drug testing.

Dr Li was awarded Direct Grant from the Chinese University of Hong Kong (2022, 2023, 2024), Young Investigator Research Grant from Hong Kong College of Physicians (2022), European Society of Medical Oncology (ESMO) Asia Travel Grant from Hong Kong Cancer Therapy Society (2022) and Young Investigator Grant from the International Association for the Study of Lung Cancer (2022), and Silver Medal in the Hong Kong Academy of Medicine Best Original Research by Young Fellows (2023). He has been an invited speaker in multiple local and regional events and conferences, including ESMO Lung Cancer advance courses, Chinese Thoracic Oncology Research Group (CTONG) conference, ESMO Asia conference, etc. Dr Li is also selected as a participant of the American Society of Clinical Oncology (ASCO) Leadership Development Programme Asia Pacific 2023-2024. He also has served in the international advisory board of the Lancet Respiratory Medicine journal. Dr Li has served as a reviewer for multiple journals including Lancet Respiratory Medicine, Journal of Thoracic Oncology, Lung Cancer, Cell Reports Medicine, Signal Transduction and Targeted Therapy, etc.

Most Representative Publications

1. Molly SC Li, Stephanie PL Saw, Alfredo Addeo. The debate on anti-CTLA4 in NSCLC: insights from NIPPON. (2024) The Lancet Respiratory Medicine. Accepted
2. Olivia H Chen, Wesley KY Wong, Kevin KS Mok, Landon L Chan, Candy HY Tang, Molly Li (corresponding author). (in press). Brief Report: Osimertinib-related QTc prolongation: real world incidence and impact of drug dosing on recurrence risk. Clinical Lung Cancer. Article in press. https://doi.org/10.1016/j.cllc.2024.06.012 
3. S. P. L. Saw, Y. F. Low, G. G. Y. Lai, L. L. Chan, W. K. Y. Wong, G. Tsui, O. H. Chen, A. O. L. Seet, W. C. Tan, A. C. Tan, J. W. K. Chan, Y. L. Teh, W. L. Tan, Q. S. Ng, M. K. Ang, R. Kanesvaran, D. W. T. Lim, D. S. W. Tan, T. S. K. Mok, M. S. C. Li. (in press). Real-world outcomes of pemetrexed-platinum chemotherapy plus osimertinib after progression on first-line osimertinib in advanced EGFR-mutated NSCLC. Lung Cancer. Article in press. https://doi.org/10.1016/k.lungcan.2024.107856
4. M. S. C. Li, S. H. I. Ou. (2024) Iruplinalkib (WX-0593), the seventh ALK TKI approved in China with more to come. Journal of Thoracic Oncology. Volume 19, Issue 6, P855-857, June 2024. https://doi.org/10.1016/j.jtho.2024.02.004
5. Molly S. C. Li, Kirsty W. C. Lee, Kevin K. S. Mok, Herbert H. F. Loong, K. C. Lam, Florence S. T. Mok, Landon L. Chan, Y. M. Lau, K. P. Chan, Joyce T. Y. Ng, Wesley K. Y. Wong, Benjamin H. W. Lam, Allen C. C. Chen, Matthew M. P. Lee, Olivia H. Chen, Tony S. K. Mok (2024) Brief Report: Risk of Recurrent Intersitial Lung Disease (ILD) from Osimertinib versus Erlotinib Rechallenge after Symptomatic Osimertinib-induced ILD. JTO Clinical and Research Reports. February 10, 2024. https://doi.org/10,1016/j.jtocrr.2024.100648
6. Molly S. C. Li, Kevin K. S. Mok, Landon L. Chan, Tony S. K. Mok. (2024) Clinical application of liquid biopsy genomic profiling in NSCLC: Asian perspectives. The Journal of Liquid Biopsy. Volume 3, March 2024, 100131. https://doi.org/10.1016/j.jlb.2023.100131
7. Li MSC, Mok KKS, Mok TSK (2023) Developments in Targeted Therapy & Immunotherapy -- how non-small cell lung cancer management will change in the next decade: a narrative review Annals of Translational Medicine. 2023 Aug 30;11(10):358. https://doi:10.21037/atm-22-4444
8. K. W. C. Lee, M. S. C. Li*, W. Gai, Y. M. Lau, A. K. C. Chan, O. S. H. Chan, C. K. Lee, R. M. W. Yeung, S. Y. H. Fung, W. F. Cheung, V. W. Chan, L. Leung, K. N. P. Kam, T. S. K. Mok. EGFR Mutation Testing in Pleural and Pericardial Effusion Cell-free DNA from Lung Cancer: A Prospective Validation Study. (*co-first authorship). JAMA Oncology. 2022 Dec 29. https://doi:10.1001/jamaoncol.2022.6109
9. M. S. C. Li, K. Mok, T. Mok (2022). A Detouring Experience Not Recommended: Lessons Learnt from PD00299804. In Cancer Research 2022 Oct 17;82(20):3662-3664. https://doi.org/10.1158/0008-5472
10. Alvin H.K. Cheung, Zeta Mui, Walter W. Yeung, C. Chow, Mandy F. Yu, Olivia H. Chen, K-Y. Wong, Fuda Xie, Y. M. Lau, Alfred S-L. Cheng, W. Kang, K-F. To, Tony S. K. Mok, Molly S.C. Li (corresponding author). Germline Human Leukocyte Antigen Status is Associated With Immunotherapy-Induced Pneumonitis and Treatment Response in Patients With Non–Small Cell Lung Cancer With High Programmed Death-Ligand 1 Expression. JTO Clinical and Research Reports. Volume 6, Issue 1, January 2025, 100754. https://doi.org/10.1016/j.jtocrr.2024.100754
11. Molly S. C. Li (corresponding author), Andrew L. S. Chan, Kevin K. S. Mok, Landon L. Chan, Tony S. K. Mok. Next-generation immunotherapy: igniting new hope for lung cancer. Therapeutic Advances in Medical Oncology. Volume 16, 2024. https://doi.org/10.1177/17588359241302021
12. S-Y. Maggie Liu, Molly S. C. Li (corresponding author). Tracking Progression of EGFR Mutation Positive NSCLC From Blood: Is This the Prime Time? Journal of Thoracic Oncology. Volume 19, Issue 11, p1482-1485, November 2024. https://doi.org/10.1016/j.jtho.2024.08.032 
13. Y. Xia, K. Wang, J. Zhao, Z. Arter, Y. Zhang, J. Zhou, Y. Lu, L. Zeng, Robyn Du, Jennifer A. Owens, Yasir Y. Elamin, Carl M. Gay, Ferdinandos Skoulidis, Anne S. Tsao, Charles Lu, Tina Cascone, Don L. Gibbons, J. Zhang, Olivia Chen, Kevin K. S. Mok, Misako Nagasaka, W. Li, John V. Heymach, S-H. Ignatius Ou, Molly Li, X. Le. Receptor tyrosine kinase fusion-mediated resistance to EGFR-TKI in EGFR-mutant NSCLC: a multi-center analysis and literature review. Journal of Thoracic Oncology. Articles in Press, November 29, 2024. https://doi.org/10.1016/j.jtho.2024.11.027
14. Stephanie P. L. Saw, W-Z. Zhong, R. Fu, Molly S. C. Li, Y. Goto, Stephen B. Fox, Y. Yatabe, B-H. Ong, Calvin S. H. Ng, David D. W. Lee, P. C. Phuong, I. K. Park, James C. H. Yang, M. Tsuboi, L. M. Tho, Thomas John, H-H. Hsu, Daniel S. W. Tan, Tony S. K. Mok, T. Reungwetwattana, N. Singh. Asian Thoracic Oncology Research Group expert consensus statement on the peri-operative management of non-small cell lung cancer. Lung Cancer (2024). 108076. https://doi.org/10.1016/j.lungcan.2024.108076 
15. Molly S. C. Li, Stephanie P. L. Saw, Alfredo Addeo. Anti-CTLA-4 in non-small-cell lung cancer: insights from the NIPPON study. The Lancet Respiratory Medicine. Volume 12, Issue 11, p840-842, November 2024. https://doi.org/10.1016/S2213-2600(24)00218-2